Teva recalls cancer drug Adrucil after rubber particles discovered in vials

Teva Pharmaceutical Industries ($TEVA) is voluntarily recalling 8 lots of Adrucil, its version of the generic cancer treatment fluorouracil. The drugmaker said the recall was initiated after particulate was found in some vials that it identified as an aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. Recall

Suggested Articles

An FDA advisory committee voted 9-1 to recommend Mesoblast's Ryoncil for approval despite some worries over its data and manufacturing.

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

AstraZeneca will work with the governments of Mexico and Argentina to produce hundreds of millions of doses of its COVID-19 vaccine hopeful.